Trump order pushes psychedelic research toward child care

Trump’s psychedelics – President Donald Trump signed an April 18 executive order to fast-track research into the medical use of psychedelics, naming federally banned substances and pointing to the mental and emotional toll felt by Americans—including roughly 6,000 military veterans

On April 18. President Donald Trump signed an executive order aimed at fast-tracking research into the medical use of psychedelics. flanked by podcaster Joe Rogan and Secretary of Health and Human Services Robert F. Kennedy, Jr. The order. according to its text. points to federally banned psychedelics as promising options for the “concerning number of Americans” struggling with mental. behavioral and emotional disorders—and it names the roughly 6. 000 military veterans who die by suicide every year.

There’s one conspicuous blank: the order does not mention minors.

Even so, experts say the policy could still move quickly toward children once the science clears adult hurdles. “It’s inevitable. because once the drug gets approved. then you start moving down that age timeline and testing kids. ” says Dominic Sisti. an associate professor of medical ethics and health policy at the University of Pennsylvania.

The executive order lands at a moment when at least one company is already seeking U.S. Food and Drug Administration approval for a treatment involving psilocybin, the active compound in magic mushrooms. The FDA has also issued priority vouchers to companies investigating the compound’s effectiveness in treating depression.

If those drugs are ultimately approved for adults in the U.S., Sisti’s prediction is that clinicians and pharmaceutical companies could eventually target people under the age of 18.

That prospect sits on a fault line familiar to pediatric medicine: adults can weigh risk and benefit for themselves. but children cannot. Robert Klitzman. a professor of psychiatry and co-founder of Columbia University’s Center for Bioethics. points out that informed consent is central to medicine. Informed consent requires patients be fully aware of a drug or procedure’s implications, both good and bad. Adults can make those decisions for themselves; for children, “the same isn’t true,” Klitzman adds.

There’s also the biology. The effects of psychedelic drugs can be more powerful and longer-lasting on a developing brain than other psychoactive medications such as antidepressants. Klitzman says. “A lot of drugs have different effects in children than in adults. and that is because the adult brain is presumably already developed. whereas a child’s brain is still developing.” If “various chemicals” are introduced while a child’s brain is still developing and learning. he says. additional risks can appear that might not show up in adults.

These risks are not abstract. Klitzman describes LSD as capable of causing “depersonalization,” a feeling of disconnection from one’s mind or body—or both. For some patients, that shift might be the intended therapeutic effect. Sisti notes that for someone suffering from a personality disorder, the disconnect might be desirable.

But diagnosing personality disorders in children is difficult. and any attempt to use psychedelic drugs in minors would require a careful. individualized analysis of costs and benefits. he says. Sisti worries the effects could ripple beyond symptoms. “I think it could alter the trajectory of a kid’s values in ways that are kind of unanticipated by parents and make parenting more complicated.” He adds that this could be a “good thing sometimes. ” but also “really disruptive to a family system.”.

The push to reconsider psychedelics for young people is not just hypothetical. Some researchers are already exploring it with safeguards built for pediatric risk.

In Sweden. a clinical trial currently underway is recruiting participants as young as age 16 to determine if psilocybin can treat anorexia nervosa. The study’s leader. David Sjöström. a doctoral student at Lund University. argues that the severity of the negative outcomes linked to the disorder can outweigh the negatives associated with the drug. He also says the science needs to answer whether the effects differ by age—specifically between a 16- and 17-year-old and someone aged 25 to 30. “We need to do robust clinical studies to get actual information on if there is an age-dependent difference,” he says.

The trial is also designed to narrow who is eligible. Lund and his team are filtering out potential participants who are considered to be at high risk of side effects. including those with a history of psychotic episodes or those at high risk of suicide. In Sweden. a 16-year-old can give consent for medical treatment. but this study requires both parents or caregivers and the child to sign off on participation as an extra precaution.

Before recruitment, the trial passed an independent safety review. Use of the drug will be closely monitored, and all doses will be administered in the presence of two therapists.

Even with those steps, Klitzman says there is a structural limitation built into psychedelic trials. It isn’t feasible to create a control group that would receive a placebo. “It turns out it’s basically impossible to blind [a clinical trial]. because people will know very quickly if they’ve had a hallucinogenic experience or not.” If researchers compare a hallucinogen with Prozac and other SSRI [selective serotonin reuptake inhibitors] antidepressants. he says. people can immediately recognize which medication they received.

Those constraints have helped shape how cautious psychedelic researchers have been—because the stakes in a pediatric trial are both clinical and ethical.

The pressure to move faster also collides with what happened before. Klitzman points to how earlier psychedelic research in children unfolded after the discovery and synthesis of psychedelic drugs such as psilocybin and LSD sparked a flurry of therapeutic speculation. That included controversial and illegal experiments like the CIA-led MKUltra brainwashing program. in which participants were unknowingly given large doses of LSD. MKUltra ran from 1953 to 1973.

The historical record also includes experiments with LSD in children: in the late 1950s. an eight-year-old girl—reported to have suffered from loss of bladder control and “serious sexual conflicts. ” as one researcher described—was given the drug. and her doctor claimed her conditions improved. In 1963. researchers gave LSD to nonverbal autistic children; some showed a reduction in aggressive behaviors. while others became more violent. engaging in actions such as pushing. biting and pinching other children. Doctors treated other children with LSD to try to address conditions such as schizophrenia, though those efforts were largely inconclusive.

Results from those early experiments were mixed. and psychedelic research in children ended in 1970 when President Richard Nixon signed the Controlled Substances Act into law. The act banned the use of many hallucinogenic drugs across the U.S. and slowed research into potential therapeutic uses, in adults and children, for generations.

Now. the so-called psychedelic renaissance that began in the early 2000s has been driven in part by pop culture figures including Rogan. and a text to Trump from the podcaster reportedly helped spur the April executive order. Some scientists are optimistic. but others temper enthusiasm because of the ethical issues involved when these compounds can drastically change a person’s behavior and neurological makeup.

Sisti and Klitzman both say the question is not whether the science could have potential—but how quickly the policy machinery moves.

Sisti doubts the executive order will produce real, well-controlled studies that wouldn’t have happened anyway. For Klitzman, the bigger worry is timing. He says the executive order could “open the floodgates too soon.” Conventional antidepressants have a high success rate in adolescents. he notes. With many outstanding questions about the long-term effects of psychedelic-based therapies. Klitzman argues for slow and cautious consideration of any potential use among young people.

“I would hope that decisions about … how these drugs are [used in treatment and therefore their availability] would be based on evidence,” Klitzman says. “Could there be benefits?. Yes. Do I have concerns?. Yes. because it is going to mean lots of people taking these drugs when there are other drugs that can help them more. and there may be some risks involved.”.

psychedelics executive order Trump psychedelics research psilocybin magic mushrooms FDA priority vouchers anorexia nervosa trial Sweden clinical trial pediatric ethics LSD MKUltra Controlled Substances Act